Genmab kept at buy by Merrill

Genmab remains a buy with a DKK150 price objective, Merrill Lynch analysts Erica Whittaker and Peter Welford said. The company reached an attractive worldwide licensing rights deal for its HuMax-CD4 with Serono SA. The drug treats a rare cancer cutaneous T-cell lymphoma. Genmab shares closed unchanged Thursday at $17.25.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.